Group 1 - The core viewpoint of the article highlights the recent performance and financial metrics of Kefu Medical (301087), indicating a slight decline in stock price and mixed capital flow on January 27, 2026 [1] - Kefu Medical reported a main revenue of 2.398 billion yuan for the first three quarters of 2025, reflecting a year-on-year increase of 6.63%, with a net profit attributable to shareholders of 260 million yuan, up 3.3% year-on-year [2] - In Q3 2025, the company achieved a single-quarter main revenue of 902 million yuan, representing a significant year-on-year increase of 30.72%, and a net profit of approximately 92.83 million yuan, up 38.68% year-on-year [2] Group 2 - The company has a debt ratio of 27.37% and reported investment income of 18.18 million yuan, with financial expenses recorded at -3.77 million yuan, indicating a healthy financial position [2] - The gross profit margin for Kefu Medical stands at 53.35%, showcasing strong profitability within its industry [2] - Over the past 90 days, 8 institutions have provided ratings for the stock, with 7 buy ratings and 1 hold rating, and the average target price set by institutions is 54.56 yuan [2]

证券之星消息，截至2026年1月26日收盘，可孚医疗(301087)报收于55.48元，下跌1.72%，换手率 1.74%，成交量3.38万手，成交额1.86亿元。 1月26日的资金流向数据方面，主力资金净流出734.45万元，占总成交额3.94%，游资资金净流入184.32 万元，占总成交额0.99%，散户资金净流入550.13万元，占总成交额2.95%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 可孚医疗2025年三季报显示，前三季度公司主营收入23.98亿元，同比上升6.63%；归母净利润2.6亿 元，同比上升3.3%；扣非净利润2.22亿元，同比上升1.46%；其中2025年第三季度，公司单季度主营收 入9.02亿元，同比上升30.72%；单季度归母净利润9282.98万元，同比上升38.68%；单季度扣非净利润 8580.27万元，同比上升62.68%；负债率27.37%，投资收益1818.06万元，财务费用-377.36万元，毛利率 53.35%。可孚医疗（301087）主营业务：家用医疗器械的研发、生产、销售和服务。 该股最近90天内共有8家机构给出评级，买入评级7家，增持评级 ...

Core Viewpoint - The accessibility industry is emerging as a significant economic growth point in China, transitioning from a welfare-focused sector to a market-driven one, driven by the aging population and the increasing needs of disabled groups [1][2]. Group 1: Industry Definition and Service Objects - The accessibility industry aims to improve, compensate, or replace human functions for groups such as the disabled, elderly, patients, and pregnant women, enhancing their quality of life and promoting social inclusion [1][2]. Group 2: Current Development Status - The market size of China's accessibility industry is projected to grow from 78 billion yuan in 2020 to 140 billion yuan by 2025, with an expected increase to 163 billion yuan by 2026 [2]. Group 3: Industry Chain - The upstream of the accessibility industry includes raw materials like metals, plastics, and electronic components, while the midstream consists of software systems and hardware products, and the downstream applications are found in homes, public buildings, and rehabilitation institutions [3]. Group 4: Development History - The accessibility industry in China has undergone four stages: the embryonic stage (2001-2007), the regulatory stage (2008-2014), the smart transformation stage (2015-2023), and the service ecosystem stage (2024-present) [3]. Group 5: Policy Environment - Recent national policies, such as the "Barrier-Free Environment Construction Law," have established a legal framework for the development of the accessibility industry, enhancing the construction of urban accessibility facilities [4]. Group 6: Competitive Landscape - Major companies in the accessibility software sector include iFlytek, SenseTime, and Tencent, while hardware companies include Yuyue Medical, Kefu Medical, and Shanghai Construction Group, among others [5][6]. - Kefu Medical reported a revenue of 1.496 billion yuan in the first half of 2025, with rehabilitation aids contributing 563 million yuan, accounting for 37.63% of total revenue [7][8]. - Yuyue Medical is a leading supplier of medical consumables, with a focus on rehabilitation care products, generating 234 million yuan in revenue from these products in the first half of 2025 [6]. Group 7: Future Development Trends - The accessibility industry is expected to expand significantly due to the aging population, with a shift from physical accessibility standards to digital, cultural, and social service areas, indicating a trend towards high-value software services and integrated solutions [9][10].

证券之星消息，截至2026年1月23日收盘，可孚医疗(301087)报收于56.45元，上涨2.28%，换手率 1.69%，成交量3.29万手，成交额1.85亿元。 1月23日的资金流向数据方面，主力资金净流入861.71万元，占总成交额4.65%，游资资金净流入764.55 万元，占总成交额4.13%，散户资金净流出1626.25万元，占总成交额8.78%。 该股主要指标及行业内排名如下： 可孚医疗2025年三季报显示，前三季度公司主营收入23.98亿元，同比上升6.63%；归母净利润2.6亿 元，同比上升3.3%；扣非净利润2.22亿元，同比上升1.46%；其中2025年第三季度，公司单季度主营收 入9.02亿元，同比上升30.72%；单季度归母净利润9282.98万元，同比上升38.68%；单季度扣非净利润 8580.27万元，同比上升62.68%；负债率27.37%，投资收益1818.06万元，财务费用-377.36万元，毛利率 53.35%。可孚医疗（301087）主营业务：家用医疗器械的研发、生产、销售和服务。 该股最近90天内共有8家机构给出评级，买入评级7家，增持评级1家；过去90天内机构目标 ...

证券日报网讯1月23日，可孚医疗（301087）在互动平台回答投资者提问时表示，截至2026年1月20日， 公司股东总户数约1.9万户。 ...

可孚医疗回复：尊敬的投资者，您好。截至2026年1月20日，公司股东总户数约1.9万户，感谢您的关 注！ 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，可孚医疗(301087)01月23日在投资者关系平台上答复投资者关心的问题。 投资者提问：领导好！我是北京的投资者，请问元月10日的股东人数市多少？谢谢！！ ...

证券之星消息，可孚医疗(301087)01月23日在投资者关系平台上答复投资者关心的问题。 投资者提问：董秘您好，请问公司到1月20日的股东人数，谢谢 可孚医疗回复：尊敬的投资者，您好。截至2026年1月20日，公司股东总户数约1.9万户，感谢您的关 注！ 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

有投资者在互动平台向可孚医疗提问："董秘您好，请问公司到1月20日的股东人数，谢谢。" 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 来源：市场资讯 针对上述提问，可孚医疗回应称："尊敬的投资者，您好。截至2026年1月20日，公司股东总户数约1.9 万户，感谢您的关注！" ...

Group 1 - The core viewpoint of the article highlights the recent performance and financial metrics of Kefu Medical (301087), indicating a slight decline in stock price and mixed capital flow on January 22, 2026 [1] - Kefu Medical reported a main revenue of 2.398 billion yuan for the first three quarters of 2025, reflecting a year-on-year increase of 6.63%, with a net profit attributable to shareholders of 260 million yuan, up 3.3% year-on-year [2] - In Q3 2025, the company achieved a single-quarter revenue of 902 million yuan, representing a significant year-on-year increase of 30.72%, and a net profit of approximately 92.83 million yuan, up 38.68% year-on-year [2] Group 2 - The company has a debt ratio of 27.37% and reported investment income of 18.18 million yuan, with financial expenses recorded at -3.77 million yuan, indicating a healthy financial position [2] - The gross profit margin for Kefu Medical stands at 53.35%, showcasing strong profitability within its industry [2] - Over the past 90 days, 8 institutions have provided ratings for the stock, with 7 buy ratings and 1 hold rating, and the average target price set by institutions is 54.56 yuan [2]

Company Overview - Kewei Medical Technology Co., Ltd. is located in Changsha, Hunan Province, and was established on November 19, 2009. The company went public on October 25, 2021. Its main business involves the research, production, sales, and service of home medical devices [1]. Business Segmentation - The revenue composition of Kewei Medical is as follows: rehabilitation aids account for 43.12%, medical care products 32.45%, health monitoring products 20.76%, and other supplementary products 3.68% [1]. Stock Performance - On January 20, Kewei Medical's stock fell by 5.02%, trading at 54.83 yuan per share, with a transaction volume of 225 million yuan and a turnover rate of 2.07%. The total market capitalization is 11.454 billion yuan [1]. Fund Holdings - According to data from the top ten holdings of funds, one fund under Xingyin Fund holds Kewei Medical shares. The Xingyin Smart Consumer Mixed A Fund (018990) held 83,800 shares in the third quarter, accounting for 4.1% of the fund's net value, making it the fifth-largest holding. The estimated floating loss today is approximately 243,000 yuan [2]. Fund Performance - The Xingyin Smart Consumer Mixed A Fund (018990) was established on November 2, 2023, with a latest scale of 19.7561 million yuan. Year-to-date returns are 4.29%, ranking 4830 out of 8848 in its category. Over the past year, the return is 32.78%, ranking 3911 out of 8093. Since inception, the return is 31.97% [2]. Fund Management - The fund manager of Xingyin Smart Consumer Mixed A is Qiao Huaguo, who has been in the position for 2 years and 74 days. The total asset size of the fund is 335 million yuan, with the best return during his tenure being 60.73% and the worst being 1.46% [3].